Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,801 to 2,820 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| ATP and Shock vs Shock Only: All-Cause Shock | 129 of 1,302 178 of 1,293 | -3.9 points -6.4 to -1.4 | 2,595 | NCT02923726 Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP |
| ATP and Shock vs Shock Only: All Cause Mortality | 196 of 1,302 174 of 1,293 | 1.6 points -1.1 to 4.3 | 2,595 | NCT02923726 Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP |
| ATP and Shock vs Shock Only: All-Cause Shock or Death From Any Cause | 297 of 1,302 322 of 1,293 | -2.1 points -5.4 to 1.2 | 2,595 | NCT02923726 Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP |
| ATP and Shock vs Shock Only: deaths from any cause | 196 of 1,302 175 of 1,293 | 1.5 points -1.2 to 4.2 | 2,595 | NCT02923726 Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP |
| ATP and Shock vs Shock Only: serious adverse events | 633 of 1,302 618 of 1,293 | 0.8 points -3.0 to 4.7 | 2,595 | NCT02923726 Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP |
| Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography | 4 of 1,290 7 of 1,304 | -0.2 points -0.8 to 0.3 | 2,594 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO: deaths from any cause | 1 of 1,727 0 of 867 | 0.1 points -0.4 to 0.3 | 2,594 | NCT03537508 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US |
| Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO: serious adverse events | 99 of 1,727 38 of 867 | 1.3 points -0.5 to 3.0 | 2,594 | NCT03537508 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US |
| Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization | 19 of 1,288 8 of 1,303 | 0.9 points 0.1 to 1.7 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF) | 66 of 1,288 48 of 1,303 | 1.4 points -0.1 to 3.1 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Failure (TLF) | 64 of 1,288 48 of 1,303 | 1.3 points -0.3 to 2.9 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR) | 13 of 1,288 3 of 1,303 | 0.8 points 0.2 to 1.5 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR | 5 of 1,288 1 of 1,303 | 0.3 points -0.1 to 0.8 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI | 59 of 1,288 47 of 1,303 | 1.0 points -0.6 to 2.5 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE) | 65 of 1,288 48 of 1,303 | 1.4 points -0.2 to 3.0 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 67 of 1,288 53 of 1,303 | 1.1 points -0.5 to 2.8 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR) | 5 of 1,288 1 of 1,303 | 0.3 points -0.1 to 0.8 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 1 of 1,288 1 of 1,303 | 0.0 points -0.4 to 0.4 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI | 59 of 1,288 48 of 1,303 | 0.9 points -0.6 to 2.5 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI) | 58 of 1,288 47 of 1,303 | 0.9 points -0.6 to 2.4 | 2,591 | NCT02173379 Absorb IV Randomized Controlled Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=141"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=141
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02923726-8f443bc4",
"title": "ATP and Shock vs Shock Only: All-Cause Shock",
"summary": "129 of 1302 against 178 of 1293; risk difference -3.9 points, 95% interval -6.4 to -1.4; NCT02923726, Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP",
"record": "/library/comparisons/NCT02923726-8f443bc4",
"nct_id": "NCT02923726",
"kind": "outcome",
"participants": 2595,
"risk_difference": {
"value": -0.038586005467226944,
"lower": -0.06351217283181079,
"upper": -0.013739993320094145
},
"group_1": "129 of 1,302",
"group_2": "178 of 1,293",
"difference": "-3.9 points",
"interval": "-6.4 to -1.4",
"trial_title": "Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP"
},
{
"id": "NCT02923726-a9c3a4f5",
"title": "ATP and Shock vs Shock Only: All Cause Mortality",
"summary": "196 of 1302 against 174 of 1293; risk difference 1.6 points, 95% interval -1.1 to 4.3; NCT02923726, Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP",
"record": "/library/comparisons/NCT02923726-a9c3a4f5",
"nct_id": "NCT02923726",
"kind": "outcome",
"participants": 2595,
"risk_difference": {
"value": 0.01596686874734926,
"lower": -0.010976762580061902,
"upper": 0.042897706372076225
},
"group_1": "196 of 1,302",
"group_2": "174 of 1,293",
"difference": "1.6 points",
"interval": "-1.1 to 4.3",
"trial_title": "Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=142",
"request_id": "EEq7ILKu4ikhaq1X"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant